Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Advertisement

CHMP Recommends Dovato Dispersible Tablets and Expanded Paediatric HIV-1 Indication – ViiV Healthcare

Written by | 22 Nov 2026 | Healthcare Practice

On 12 November 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending changes to the terms of the marketing authorisation for the medicinal product Dovato. The marketing authorisation holder for this medicinal product is ViiV Healthcare B.V.

The CHMP adopted a new indication associated with new Dovato 5 mg / 30 mg dispersible tablets, as follows:

Dovato is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in children at least 3 months of age, weighing at least 6 kg to less than 25 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine (see section 5.1).

The CHMP also adopted an extension to the existing indication for Dovato 50 mg / 300 mg film-coated tablets, as follows:

Dovato is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults, adolescents and children weighing at least 20 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.

Source: European Medicines Agency (EMA) – Dovato: CHMP positive opinion on variation to marketing authorisation

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.